PF-06700841 (Brepocitinib) is a dual inhibitor of JAK1 and TYK2, with IC50 values of 17 nM and 23 nM, respectively. PF-06700841 (Brepocitinib) inhibits EPO/pSTAT5 (JAK2 homodimer) in HWB spiked with CD34+ progenitor cells (IC50 of 577 nM). PF-06700841 also inhibits the JAK1/JAK3 driven γ-common chain cytokines, represented by IL-15/pStat5 and IL-21/pSTAT3 with reasonable potency (HWB IC50s of 238 and 204 nM, respectively).
|Solubility (25°C)||DMSO 57 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Andrew Fensome, et al. J Med Chem. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
 Christopher Banfield, et al. J Clin Pharmacol. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
|Related JAK Products|
SDC-1802 is a JAK1/TYK2 inhibitor that can be used in studies related to systemic lupus erythematosus.
OST-246 is an inhibitor of JAK3, MAP3K11, and TYK2 for studies related to autoimmune diseases and inflammation.
NDI-031232 is a TYK2 inhibitor.
NDI-031301 is a TYK2 inhibitor.
NDI-031407 is a TYK2 inhibitor for studies related to endocrine metabolic diseases and psoriasis.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.